查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1822423

2032 年註意力不足过动症和自闭症数位治疗市场预测：按产品、年龄层、治疗重点、交付模式、最终用户和地区进行的全球分析

Digital Therapeutics for ADHD & Autism Market Forecasts to 2032 - Global Analysis By Product (Software Applications, Devices (Wearables) and Platforms (Telehealth Solutions)), Age Group, Therapeutic Focus, Delivery Mode, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球注意力不足过动症和自闭症数位疗法市场规模预计在 2025 年达到 13 亿美元，到 2032 年将达到 54 亿美元，预测期内的复合年增长率为 21.7%。

针对注意力不足过动症 (ADHD) 和自闭症的数位疗法 (DTx) 是基于循证的、软体驱动的主导，旨在预防、管理和治疗这些神经发育障碍的症状。 DTx 利用应用程式、电玩游戏和互动式等数位平台来提高注意力、认知灵活性、情绪调节和社交技能。 DTx 是传统治疗方法的补充，提供个人化、引人入胜且扩充性的治疗方法。这些数位解决方案经过临床检验，通常由医疗保健专业人员开立处方，可提供持续监测、自适应学习和行为回馈，以改善患者预后，同时减少对药物的依赖并支持长期发展进步。

数位健康的科技进步

数位疗法可实现个人化介入、即时进度追踪和远端互动。与行为分析、言语治疗和认知训练的结合正在改善治疗效果。学校、诊所和看护者正在采用科技工具来支持神经病变患者。公共和私营部门对数位医疗基础设施的投资正在增强其应用。这些动态使数位创新成为过动症和自闭症治疗市场的关键驱动力，并推动整体市场成长。

监管和报销挑战

开发者面临着许多挑战，例如获得核准、检验临床有效性以及遵守资料隐私法。付款方对非传统治疗方法的承保持谨慎态度，这影响了其可及性。数位健康政策和审批的地区差异使部署变得复杂。缺乏标准化的结果指标阻碍了可扩展性和信任。儘管技术发展势头强劲，但这些因素仍在限制市场扩张。

扩大投资和市场潜力

创业投资、政府津贴和策略伙伴关係正在加速产品开发和平台整合。教育机构、雇主和医疗保健提供者正在投资扩充性且依证的数位解决方案。对非侵入性、个人化和便利治疗方法的需求正在推动创新。公共卫生计划和全面的教育要求正在推动数位疗法的普及。这些新兴市场的发展为市场成长创造了有利条件，并加速了数位疗法的普及。

成本和可访问性问题

数位素养差距和基础设施限制影响用户参与度和留存率。服务提供者必须投资在地化、可负担性和混合交付模式，以克服障碍。网路存取和设备可用性方面的差异降低了农村和服务欠缺地区的采用率。与传统护理途径的整合有限，减缓了临床应用。这些限制构成系统性风险，并限制了全面的市场发展。

COVID-19的影响：

新冠疫情扰乱了注意力不足过动症 (ADHD) 和自闭症数位疗法市场，导致临床检验、平台部署和现场评估暂时延迟。教育机构、治疗中心和诊断实验室的容量减少影响了护理的连续性。然而，对心理健康、远端参与和数位优先干预措施的关注度增加部分抵消了市场放缓的影响。疫情后的復苏得益于对可访问、技术支援和个人化神经发育支援解决方案的需求增长，以及各个使用者群体在虚拟治疗平台和居家干预方面的创新。

预计软体应用领域将成为预测期内最大的领域

软体应用领域预计将在预测期内占据最大的市场份额，这得益于其扩充性、成本效益以及跨装置和平台的便利整合。行动应用程式、基于网路的工具和人工智慧主导的介面正在实现即时监控、自适应学习和行为强化。供应商正在优化演算法，以提供针对特定年龄、适应文化并经过临床检验的干预措施。医疗保健、教育和居家照护领域的需求仍然强劲。监管部门对数位健康和​​数据互通性的支持正在推动其应用。该领域将继续支持数位治疗市场，推动整体市场成长。

预计教育领域在预测期内将以最高的复合年增长率成长

预计教育领域将在预测期内实现最高成长率，这得益于对神经病变学生全面、技术赋能和可扩展支援的需求。学校正在采用数位治疗方法来改善学习成果、减少行为障碍并支持个人化教育计画。与课堂工具、教师仪表板和学生进度追踪器的整合正在提高学生的参与度和课责。特殊教育的公共资金和政策授权正在加速其应用。对基于证据的、可访问的解决方案的需求正在积聚势头，加速市场扩张。

占比最大的地区：

在预测期内，北美预计将占据最大的市场份额，这得益于其先进的数位健康生态系统、强大的报销基础设施以及对神经发育障碍的高度认知。美国和加拿大在临床检验、平台部署和监管核准处于主导地位。心理健康、全纳教育和数位疗法领域的公共倡议正在增强需求。区域新兴企业和学术机构正在推动人工智慧、使用者体验设计和治疗内容的创新。保险覆盖和学校项目正在支持相关技术的采用。

复合年增长率最高的地区：

预计亚太地区在预测期内的复合年增长率最高，这得益于儿科人口的增长、数位基础设施的扩展以及政府对神经发育护理的投入。中国、印度、日本和韩国等国家正在扩大学校筛检、行动医疗平台和全纳教育计画。官民合作关係和行动优先策略正在改善都市区和半都市区的医疗服务可近性。对价格合理、文化适应性强且多语言工具的需求正在推动创新。

免费客製化服务：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球注意力不足过动症和自闭症数位治疗市场（按产品）

  • 软体应用程式
  • 装置（穿戴式装置）
  • 平台（远端医疗解决方案）

6. 全球注意力不足过动症和自闭症数位治疗市场（按年龄层）

  • 孩子
  • 青年
  • 成人

7. 全球注意力不足过动症和自闭症数位治疗市场（按治疗重点）

  • 认知行为治疗（CBT）
  • 社交技能培训
  • 注意力训练
  • 睡眠管理
  • 焦虑和压力管理

8. 全球注意力不足过动症和自闭症数位治疗市场（按交付模式）

  • 行动应用程式
  • 网路为基础的平台
  • 虚拟实境（VR）
  • 扩增实境（AR）

9. 全球注意力不足过动症和自闭症数位治疗市场（按最终用户划分）

  • 个人
  • 医疗保健提供者
  • 教育机构
  • 看护者和家人
  • 雇主和职场
  • 其他最终用户

10. 全球注意力不足过动症和自闭症数位治疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第 12 章：公司概况

  • Cognoa Inc.
  • Akili, Inc.
  • Pear Therapeutics, Inc.
  • CogniFit Inc.
  • BrainWare Learning Company
  • Neurocog Trials, Inc.
  • Headspace Health
  • Mightier
  • Elemy Health
  • Floreo Inc.
  • NeuroFlow Inc.
  • Limbix Health, Inc.
  • Total Brain
  • Koa Health
  • Bold Health
Product Code: SMRC31178

According to Stratistics MRC, the Global Digital Therapeutics for ADHD & Autism Market is accounted for $1.3 billion in 2025 and is expected to reach $5.4 billion by 2032 growing at a CAGR of 21.7% during the forecast period. Digital Therapeutics (DTx) for ADHD and Autism are evidence-based, software-driven interventions designed to prevent, manage, or treat symptoms of these neurodevelopmental disorders. Utilizing digital platforms such as apps, video games, and interactive programs, DTx aim to improve attention, cognitive flexibility, emotional regulation, and social skills. They complement traditional therapies, providing personalized, engaging, and scalable treatment options. Clinically validated and often prescribed by healthcare professionals, these digital solutions offer continuous monitoring, adaptive learning, and behavioral feedback, enhancing patient outcomes while reducing reliance on medication and supporting long-term developmental progress.

Market Dynamics:

Driver:

Technological advancements in digital health

Digital therapeutics are enabling personalized interventions, real-time progress tracking, and remote engagement. Integration with behavioral analytics, speech therapy, and cognitive training is enhancing treatment outcomes. Schools, clinics, and caregivers are adopting tech-enabled tools to support neurodiverse individuals. Public and private investments in digital health infrastructure are reinforcing adoption. These dynamics are positioning digital innovation as a key driver of the ADHD & autism therapeutics market, thereby boosting overall market growth.

Restraint:

Regulatory and reimbursement challenges

Developers face hurdles in securing approvals, validating clinical efficacy, and navigating data privacy laws. Payers remain cautious about coverage for non-traditional interventions, affecting accessibility. Regional disparities in digital health policy and licensing are complicating deployment. Lack of standardized outcome metrics is hindering scalability and trust. These factors are tempering market expansion despite strong technological momentum.

Opportunity:

Growing investment and market potential

Venture capital, government grants, and strategic partnerships are accelerating product development and platform integration. Educational institutions, employers, and healthcare providers are investing in scalable, evidence-based digital solutions. Demand for non-invasive, personalized, and accessible therapies is reinforcing innovation. Public health initiatives and inclusive education mandates are supporting adoption. These developments are creating favorable conditions for market growth, thereby accelerating uptake of digital therapeutics.

Threat:

Cost and accessibility issues

Digital literacy gaps and infrastructure constraints are affecting user engagement and retention. Providers must invest in localization, affordability, and hybrid delivery models to overcome barriers. Disparities in internet access and device availability are reducing reach in rural and underserved regions. Limited integration with traditional care pathways is slowing clinical adoption. These limitations are introducing systemic risk and constraining full-scale market development.

Covid-19 Impact:

The Covid-19 pandemic disrupted the Digital Therapeutics for ADHD & Autism market, causing temporary delays in clinical validation, platform deployment, and in-person assessments. Educational institutions, therapy centers, and diagnostic facilities experienced reduced capacity, impacting continuity of care. However, the increased focus on mental health, remote engagement, and digital-first interventions partially offset the slowdown. Post-pandemic recovery is driven by growing demand for accessible, tech-enabled, and personalized neurodevelopmental support solutions, along with innovations in virtual therapy platforms and home-based interventions across user segments.

The software applications segment is expected to be the largest during the forecast period

The software applications segment is expected to account for the largest market share during the forecast period owing to its scalability, cost-efficiency, and ease of integration across devices and platforms. Mobile apps, web-based tools, and AI-driven interfaces are enabling real-time monitoring, adaptive learning, and behavioural reinforcement. Providers are optimizing algorithms for age-specific, culturally adaptive, and clinically validated interventions. Demand remains strong across healthcare, education, and homecare domains. Regulatory support for digital health and data interoperability is reinforcing adoption. This segment continues to anchor the digital therapeutics market, thereby boosting overall market growth.

The educational institutions segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the educational institutions segment is predicted to witness the highest growth rate driven by demand for inclusive, tech-enabled, and scalable support for neurodiverse students. Schools are adopting digital therapeutics to enhance learning outcomes, reduce behavioural disruptions, and support individualized education plans. Integration with classroom tools, teacher dashboards, and student progress trackers is improving engagement and accountability. Public funding and policy mandates for special education are accelerating deployment. Demand for evidence-based, accessible solutions is reinforcing momentum, thereby accelerating market expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced digital health ecosystem, strong reimbursement infrastructure, and high awareness of neurodevelopmental conditions. The U.S. and Canada are leading in clinical validation, platform deployment, and regulatory approvals. Public initiatives in mental health, inclusive education, and digital therapeutics are reinforcing demand. Regional startups and academic institutions are driving innovation in AI, UX design, and therapeutic content. Insurance coverage and school-based programs are supporting widespread adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rising paediatric population, expanding digital infrastructure, and government investment in neurodevelopmental care. Countries like China, India, Japan, and South Korea are scaling school-based screening, mobile health platforms, and inclusive education programs. Public-private partnerships and mobile-first strategies are improving access in urban and semi-urban areas. Demand for affordable, culturally adaptive, and multilingual tools is reinforcing innovation.

Key players in the market

Some of the key players in Digital Therapeutics for ADHD & Autism Market include Cognoa Inc., Akili, Inc., Pear Therapeutics, Inc., CogniFit Inc., BrainWare Learning Company, Neurocog Trials, Inc., Headspace Health, Mightier, Elemy Health, Floreo Inc., NeuroFlow Inc., Limbix Health, Inc., Total Brain, Koa Health and Bold Health.

Key Developments:

In July 2025, Cognoa expanded partnerships with Highmark Health and HTAhealth, enabling broader access to its AI-powered autism diagnostic, Canvas Dx, for self-insured employers and commercial health plans. These collaborations support scalable deployment and reimbursement of digital diagnostics across pediatric populations.

In March 2024, Akili entered a strategic partnership with Shionogi & Co. Ltd. to commercialize its ADHD and autism digital therapeutics in Japan and Taiwan, with milestone payments up to $125M. Shionogi will lead clinical development and marketing, while Akili manages global platform operations and data compliance.

Products Covered:

  • Software Applications
  • Devices (Wearables)
  • Platforms (Telehealth Solutions)

Age Groups Covered:

  • Children
  • Adolescents
  • Adults

Therapeutic Focuses Covered:

  • Cognitive Behavioural Therapy (CBT)
  • Social Skills Training
  • Attention Training
  • Sleep Management
  • Anxiety and Stress Management

Delivery Modes Covered:

  • Mobile Applications
  • Web-Based Platforms
  • Virtual Reality (VR)
  • Augmented Reality (AR)

End Users Covered:

  • Individuals
  • Healthcare Providers
  • Educational Institutions
  • Caregivers and Families
  • Employers & Workplace
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Therapeutics for ADHD & Autism Market, By Product

  • 5.1 Introduction
  • 5.2 Software Applications
  • 5.3 Devices (Wearables)
  • 5.4 Platforms (Telehealth Solutions)

6 Global Digital Therapeutics for ADHD & Autism Market, By Age Group

  • 6.1 Introduction
  • 6.2 Children
  • 6.3 Adolescents
  • 6.4 Adults

7 Global Digital Therapeutics for ADHD & Autism Market, By Therapeutic Focus

  • 7.1 Introduction
  • 7.2 Cognitive Behavioral Therapy (CBT)
  • 7.3 Social Skills Training
  • 7.4 Attention Training
  • 7.5 Sleep Management
  • 7.6 Anxiety and Stress Management

8 Global Digital Therapeutics for ADHD & Autism Market, By Delivery Mode

  • 8.1 Introduction
  • 8.2 Mobile Applications
  • 8.3 Web-Based Platforms
  • 8.4 Virtual Reality (VR)
  • 8.5 Augmented Reality (AR)

9 Global Digital Therapeutics for ADHD & Autism Market, By End User

  • 9.1 Introduction
  • 9.2 Individuals
  • 9.3 Healthcare Providers
  • 9.4 Educational Institutions
  • 9.5 Caregivers and Families
  • 9.6 Employers & Workplace
  • 9.7 Other End Users

10 Global Digital Therapeutics for ADHD & Autism Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Cognoa Inc.
  • 12.2 Akili, Inc.
  • 12.3 Pear Therapeutics, Inc.
  • 12.4 CogniFit Inc.
  • 12.5 BrainWare Learning Company
  • 12.6 Neurocog Trials, Inc.
  • 12.7 Headspace Health
  • 12.8 Mightier
  • 12.9 Elemy Health
  • 12.10 Floreo Inc.
  • 12.11 NeuroFlow Inc.
  • 12.12 Limbix Health, Inc.
  • 12.13 Total Brain
  • 12.14 Koa Health
  • 12.15 Bold Health

List of Tables

  • Table 1 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Software Applications (2024-2032) ($MN)
  • Table 4 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Devices (Wearables) (2024-2032) ($MN)
  • Table 5 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Platforms (Telehealth Solutions) (2024-2032) ($MN)
  • Table 6 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Age Group (2024-2032) ($MN)
  • Table 7 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Children (2024-2032) ($MN)
  • Table 8 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Adolescents (2024-2032) ($MN)
  • Table 9 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Adults (2024-2032) ($MN)
  • Table 10 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Therapeutic Focus (2024-2032) ($MN)
  • Table 11 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Cognitive Behavioral Therapy (CBT) (2024-2032) ($MN)
  • Table 12 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Social Skills Training (2024-2032) ($MN)
  • Table 13 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Attention Training (2024-2032) ($MN)
  • Table 14 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Sleep Management (2024-2032) ($MN)
  • Table 15 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Anxiety and Stress Management (2024-2032) ($MN)
  • Table 16 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Delivery Mode (2024-2032) ($MN)
  • Table 17 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Mobile Applications (2024-2032) ($MN)
  • Table 18 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Web-Based Platforms (2024-2032) ($MN)
  • Table 19 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Virtual Reality (VR) (2024-2032) ($MN)
  • Table 20 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Augmented Reality (AR) (2024-2032) ($MN)
  • Table 21 Global Digital Therapeutics for ADHD & Autism Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Individuals (2024-2032) ($MN)
  • Table 23 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Healthcare Providers (2024-2032) ($MN)
  • Table 24 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Educational Institutions (2024-2032) ($MN)
  • Table 25 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Caregivers and Families (2024-2032) ($MN)
  • Table 26 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Employers & Workplace (2024-2032) ($MN)
  • Table 27 Global Digital Therapeutics for ADHD & Autism Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.